Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusiness

Lupin gets USFDA nod for Asthma drug

The product approved by the United States Food and Drug Administration (USFDA) is a generic version of AstraZeneca Pharmaceuticals LP's Pulmicort Respules Inhalation Suspension, 0.5 mg/2 mL, Lupin said in a regulatory filing.

November 13, 2018 / 01:08 PM IST
Lupin | Rakesh Jhunjhunwala increased stake in company to 1.53 percent in September quarter, from 1.47 percent in June quarter; LIC also raised stake to 3.71 percent from 2.7 percent and MFs to 12.58 percent from 11.94 percent. (Image: Reuters)

Lupin | Rakesh Jhunjhunwala increased stake in company to 1.53 percent in September quarter, from 1.47 percent in June quarter; LIC also raised stake to 3.71 percent from 2.7 percent and MFs to 12.58 percent from 11.94 percent. (Image: Reuters)

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug major Lupin on Tuesday said it has received approval from the US health regulator to market Budesonide Inhalation Suspension single-dose ampules, used for treating Asthma.

The product approved by the United States Food and Drug Administration (USFDA) is a generic version of AstraZeneca Pharmaceuticals LP's Pulmicort Respules Inhalation Suspension, 0.5 mg/2 mL, Lupin said in a regulatory filing.

Quoting IQVIA MAT September data, Lupin said, the said Asthma drug had annual sales of around USD 474.5 million in the US.

Shares of Lupin were Tuesday trading 1.30 per cent down at Rs 849.30 apiece on the BSE.

PTI
first published: Nov 13, 2018 01:05 pm

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347